AVXL Stock UPDATES Anavex Life Sciences (AVXL) 0.2600 08/11/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Anavex Life Sciences (AVXL) 0.2600 $AVXL

Anavex Appoints Experienced Pharma Executive as Vice President of Clinical Operations
GlobeNewswire - Thu Aug 07, 6:48AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company" (OTCQB: AVXL), a clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's disease, other diseases of the central nervous system (CNS) and various types of cancer, announced today the appointment of Tasos Zografidis, PhD as Vice President, Clinical Operations. In this newly created position, Dr. Zografidis will be responsible for managing Anavex's clinical programs, including the upcoming Phase 2a clinical trial for ANAVEX 2-73 and ANAVEX PLUS, the Company's lead drug candidate combination in Alzheimer's disease.

Anavex Achieves Key Milestone as it Secures cGMP Manufacturing for Drug Candidate Trial Supplies
GlobeNewswire - Mon Jul 21, 6:27AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company" (OTCQB:AVXL), a clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's disease, other diseases of the central nervous system (CNS) and various types of cancer, today announced that it has secured cGMP manufacturing of ANAVEX 2-73 for its drug candidate trial supplies.

ANAVEX 3-71 Highly Effective and Disease-Modifying Against All Major Alzheimer's Hallmarks in Preclinical Disease Model
GlobeNewswire - Mon Jul 14, 6:27AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company" (OTCQB:AVXL), a clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's disease, other diseases of the central nervous system (CNS) and various types of cancer, has unveiled promising preclinical data for ANAVEX 3-71 (formerly AF710B) in a presentation at the 2014 Alzheimer's Association International Conference (AAIC).

Anavex Announces Report Expanding Opportunity for Therapeutic Application of Anavex Compounds
GlobeNewswire - Mon Jun 30, 6:27AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company" (OTCQB:AVXL), a clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's disease, other diseases of the central nervous system (CNS) and various types of cancer, today announced that a paper in the current issue of the peer-reviewed scientific journal, Neurochemical Research, reveals for the first time that sigma-1 receptors (S1R) functionally downregulate certain proteins that play a major role in various pathophysiological conditions including depression, anxiety, epilepsy and brain injury following ischemic stroke.

Acute Pain - Pipeline Review, H1 2014
M2 - Wed Jun 11, 5:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qlbxfm/acute_pain) has announced the addition of the "Acute Pain - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Acute Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Pain and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Scope - The report provides a snapshot of the global therapeutic landscape of Acute Pain - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Acute Pain and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects Companies Mentioned: - Nektar Therapeutics - Santen Pharmaceutical Co., Ltd. - Pacira Pharmaceuticals, Inc. - AcelRx Pharmaceuticals, Inc. - Laboratorios Del Dr. Esteve S.A. - Pfizer Inc. - Sigma-Tau S.p.A. - A. Menarini Industrie Farmaceutiche Riunite Srl - Anavex Life Sciences Corp. - Nuvo Research Inc. - Zalicus Inc. - Yungjin Pharm Ind. Co., Ltd. - Array BioPharma Inc. - Orexo AB - Insys Therapeutics, Inc. - Grunenthal GmbH - AngioChem Inc. - Charleston Laboratories, Inc. - Trevena, Inc. - Syntrix Biosystems, Inc. - Kineta, Inc. - QRxPharma Limited - Cara Therapeutics, Inc. - Iroko Pharmaceuticals, LLC - Encore Therapeutics Inc. - Madeira Therapeutics For more information visit http://www.researchandmarkets.com/research/qlbxfm/acute_pain

Anavex wins new US patent for ANAVEX 3-71 for treating Alzheimer's disease (AD), type 2 diabetes and insulin resistance
M2 - Thu Jun 05, 3:25AM CDT
Biopharmaceutical company Anavex Life Sciences (Other OTC:AVXL) disclosed on Wednesday the receipt of the US Patent Number 8,673,931 covering ANAVEX 3-71 (formerly AF710B) for treating Alzheimer's disease (AD), type 2 diabetes and insulin resistance.

Anavex Awarded New U.S. Patent
GlobeNewswire - Wed Jun 04, 6:27AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company" (OTCQB:AVXL), a clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's disease, other diseases of the central nervous system (CNS) and various types of cancer, is pleased to announce that it has been issued U.S. Patent No. 8,673,931 (the "Patent" . The composition and method Patent covers ANAVEX 3-71 (formerly AF710B) for treating Alzheimer's disease (AD), type 2 diabetes and insulin resistance. ANAVEX obtained exclusive rights to worldwide patents and patent applications for ANAVEX 3-71 and related compounds in March 2014 from Life Science Research Israel, a subsidiary of the Israel Institute for Biological Research. The Patent has a term that expires no earlier than April 29, 2030.

Anavex Strengthens Alzheimer's Pipeline, Obtains Exclusive Worldwide Rights to Intellectual Property
GlobeNewswire - Mon Mar 31, 7:15AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company" (OTCQB:AVXL), a clinical stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's, diseases of the central nervous system (CNS) and various types of cancer, announced today that it has strengthened its Alzheimer's pipeline by obtaining exclusive rights to worldwide patents and patent applications covering methods and compositions for AF710B and other related, preclinical stage compounds from Life Science Research Israel Ltd. (LSRI). LSRI has a proven track record of successfully developing and bringing drugs to market. The licensing of AF710B complements Anavex's existing pipeline in Alzheimer's disease, which is the company's core competency and includes lead clinical candidate ANAVEX PLUS.

Anavex Reports Predicted Clinical Effect of Both ANAVEX 2-73 and ANAVEX PLUS in a Humanized Cortical Cognitive Model for Alzheimer's Disease
GlobeNewswire - Thu Mar 27, 12:00PM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company" (OTCQB:AVXL), a clinical stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's, diseases of the central nervous system (CNS) and various types of cancer, today announced that a report in the current issue of peer-reviewed International Pharmaceutical Industry Journal ("IPI Journal" predicts that ANAVEX 2-73 will have a meaningful effect in Alzheimer's disease based on the Alzheimer's Disease Assessment Scale-Cognitive ("ADAS-Cog" , especially when combined with donepezil (Aricept(R)), the world's best-selling Alzheimer's drug. The Company believes this drug combination, called ANAVEX PLUS, is a compelling commercial opportunity because of its potential to treat symptoms of Alzheimer's while also possibly modifying or reversing the course of the disease. A Phase 1b/2a clinical trial of ANAVEX PLUS, is scheduled to begin mid 2014.

Anavex Successfully Closes $10 Million Financing to Initiate Phase 1b/2a Alzheimer's Clinical Trial
GlobeNewswire - Wed Mar 19, 6:37AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company" (OTCQB:AVXL), a clinical stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's, diseases of the central nervous system (CNS) and various types of cancer, announced today that it has closed, as previously announced on March 13, 2014, the private placement of $10 million in principal amount of convertible debentures with several institutional and accredited investors, including U.S. and international healthcare funds. In addition, the investors received warrants to purchase up to approximately 66.7 million shares of common stock in the aggregate.

Anavex Life Sciences signs USD10m private placement to execute clinical trial Phase 1b/2a in Alzheimer's and advance product portfolio
M2 - Fri Mar 14, 4:01AM CDT
Biopharmaceutical company Anavex Life Sciences (Other OTC:AVXL) said on Thursday that it has signed a private placement of USD10m of convertible debentures with several institutional and accredited investors, including US and international healthcare funds,.

Anavex Announces $10 Million Private Placement of Convertible Debentures
GlobeNewswire - Thu Mar 13, 9:36AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company" (OTCQB:AVXL), a clinical stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's, diseases of the central nervous system (CNS) and various types of cancer, announced today that it has entered into definitive agreements with several institutional and accredited investors, including U.S. and international healthcare funds, for a private placement of approximately $10 million in principal amount of convertible debentures. In addition, the investors will receive warrants to purchase up to approximately 66.7 million shares of common stock in the aggregate.

Anavex Encouraged By Scientific Data Confirming Sigma-1 Receptor Agonist Extends Survival in ALS (Lou Gehrig's Disease)
GlobeNewswire - Mon Mar 10, 6:39AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company" (OTCQB:AVXL), a clinical stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's, diseases of the central nervous system (CNS) and various types of cancer, today announced the findings of a research report published in the current issue of peer-reviewed scientific journal Neuroscience Letters. The Company is encouraged by the report because its results point to potential for ANAVEX 2-73 to treat ALS, also known as Lou Gehrig's disease. Data showed that sigma-1 receptor (S1R) agonists are effective in suppressing motor neuron degeneration and symptom progression in ALS animal models.

Anavex: Research Report Reveals Cardioprotective Action of Sigma-1 Receptor Agonists
GlobeNewswire - Tue Mar 04, 6:33AM CST
Anavex Life Sciences Corp. ("Anavex" or the "Company" (OTCQB:AVXL) is encouraged by the findings of a research report published in the current issue of peer-reviewed scientific journal Life Sciences. Among its conclusions, the report reveals that sigma-1 receptor (S1R) agonists play an important role in the prevention, delay or reduction of heart disease. These findings correlate with the positive electrocardiogram (EKG) parameters in the successfully completed human clinical Phase 1 safety trial of ANAVEX 2-73, an orally available S1R agonist drug candidate developed to treat Alzheimer's through potential disease modification. ANAVEX 2-73 has also shown highly encouraging synergy with donepezil, the world's best-selling Alzheimer's drug, and a Phase 1b/2a clinical trial of this combination, ANAVEX PLUS, is planned for the first half of 2014.

Research Report Confirms Opportunity for Anavex Anti-Cancer and Neuropathic Pain Compounds
GlobeNewswire - Wed Feb 26, 7:42AM CST
Anavex Life Sciences Corp. ("Anavex" or the "Company" (OTCQB:AVXL) today announced that a research article in the current issue of peer-reviewed scientific journal Molecular Pain reveals a new opportunity for the Company's anti-cancer and neuropathic pain compounds. The article describes that sigma-1 receptor (S1R) modulation prevents neuropathic pain and mitochondrial abnormalities induced by the chemotherapy drug paclitaxel.

Anavex to Present at 16th Annual BIO CEO & Investor Conference
GlobeNewswire - Mon Feb 03, 6:27AM CST
Anavex Life Sciences Corp. ("Anavex" or the "Company" (OTCQB:AVXL) today announced that Christopher U. Missling, PhD, President and Chief Executive Officer, will be presenting at the 16th Annual BIO CEO & Investor Conference on Monday, February 10, 2014, at 1:00 p.m. ET in the Conrad Room. The conference will be held at the Waldorf-Astoria Hotel in New York, NY.

Sigma-1 receptor Implicated in Cell Survival of Rare Neurodegenerative Diseases - Expanding the Opportunity for Application of ANAVEX PLUS in Rare Diseases
GlobeNewswire - Thu Jan 23, 6:17AM CST
Anavex Life Sciences Corp. ("Anavex" or the "Company" (OTCQB:AVXL) today announced that a publication in the current issue of scientific journal Neuropathology potentially extends the opportunity for ANAVEX PLUS to additional neurodegenerative diseases beyond Alzheimer's.

Anavex Agreement With The Roskamp Institute to Advance the Clinical Development of ANAVEX PLUS
GlobeNewswire - Tue Jan 14, 4:15PM CST
Anavex Life Sciences Corp. ("Anavex" or the "Company" (OTCQB:AVXL) today announced that they have established an agreement with The Roskamp Institute for the clinical development of ANAVEX PLUS, a new combination drug of ANAVEX 2-73 and donepezil (Aricept(R)) for the treatment of Alzheimer's disease. This study will evaluate the safety, tolerability, pharmacokinetics, and possible clinical benefits of ANAVEX PLUS in Alzheimer's disease patients and other diseases associated with dementia and cognitive impairment.




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 258

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading
ModuleMD Takes Allergy EHR AI Beyond the Usual Hype Cycle

Updated Category News Views 334

Allergy Workflows Are Where This Has to Earn Its Keep Allergy clinics do not need another shiny dashboard clogging up a workstation. They need less typing, fewer handoffs, cleaner documentation, and fewer administrative chores slipping through the cracks while a packed day keeps moving. That is the practical lens for ModuleMD's ACAAI 2026 presentation in Phoenix: not...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 333

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 282

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 546

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
Newegg’s GIGABYTE Event Is Brand Work, Not a Catalyst

Updated Category News Views 461

A 2,300-square-foot room can tell a retailer plenty about its tribe. On November 21, Newegg is turning its Diamond Bar Gamer Zone into the home base for GIGABYTE’s AORUS VS40 celebration, a free five-hour event marking the hardware maker’s 40th anniversary. There will be 1v1 VALORANT and League of Legends contests, demo stations, raffles, anniversary merchandise, food...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 466

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 289

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 411

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
NatGasHub’s 391% Growth Signals a Real Pipeline Shift

Updated Category News Views 335

Three hundred-plus pipelines is a lot of messy plumbing to tame, and NatGasHub has apparently found a lucrative way to do it. The Houston software company landed at No. 182 on Deloitte’s 2026 Technology Fast 500 after reporting 391% revenue growth from 2022 through 2025. That is a serious number, even in a ranking built to showcase companies sprinting uphill. More...

Continue Reading

Top 5 Most Recently Viewed Articles

OneStream Shines as a 5-Time Leader in 2025 Gartner Magic Quadrant

Updated Category News Views 232

OneStream Recognized as a Leader in Financial Planning Software OneStream has achieved significant recognition in the financial planning software landscape by being named a leader in the 2025 Gartner Magic Quadrant. This achievement reflects their exceptional performance in both the Ability to Execute and Completeness of Vision categories. As businesses strive to...

Continue Reading
U.S. Bancorp Welcomes New Head of Consumer Payments Team

Updated Category News Views 307

U.S. Bancorp Appoints New Head of Consumer Payments U.S. Bancorp (BVMF: USBC34) (NYSE: USB) has made a significant move in its leadership with the appointment of Courtney Kelso as the senior executive vice president and head of Payments: Consumer and Small Business (PCS). This announcement underscores U.S. Bancorp's commitment to enhancing its consumer payment solutions...

Continue Reading
The Incredible Growth of Amphenol: A 20-Year Journey

Updated Category News Views 171

Exploring Amphenol's Long-Term Investment Potential Amphenol (NYSE: APH) has shown impressive returns in the stock market over the last two decades. With an average annual return of 22.23%, it has outperformed many market indices by 13.37% on an annualized basis. As of now, Amphenol boasts a market capitalization of approximately $167.52 billion, showcasing its stability...

Continue Reading
ASTM Announces Enhanced Direct Access to Cutting-Edge Platform

Updated Category News Views 361

ASTM's Enhanced Direct Access to Compass Platform Change in reseller relationship invites direct access through ASTM Compass. To better serve its customers' growing demand for advanced digital formats and efficient workflows, ASTM International is shifting its focus to direct sales. This decision comes as they will no longer continue their long-standing reseller...

Continue Reading
Berry Corporation Enhances Financial Framework with Refinancing

Updated Category News Views 108

Berry Corporation's Strategic Refinancing Initiative Berry Corporation (NASDAQ: BRY) has made headlines with the significant completion of a comprehensive refinancing strategy aimed at strengthening its financial foundation. This move, which occurred recently, marks a pivotal moment for the company, enhancing its capital and liquidity and enabling the firm to accelerate...

Continue Reading